MultivisionDx, a Finnish healthtech startup, specializes in AI tools for personalized cancer diagnostics. Recently, the company secured €1 million in a pre-seed funding round led by Antler, joined by Helsinki University Funds, Kaikarhenni Oy, and a Finnish healthcare angel investor. Founded in 2025, MultivisionDx leverages spatial biology and computer vision, rooted in research from the University of Helsinki, to analyze tumor biology and microenvironments. Their AI-powered decision-support tools assist clinicians in assessing cancer aggressiveness, enabling tailored therapies for patients with solid tumors.
CEO Michael Wittinger emphasized that this investment is critical for translating scientific discoveries into impactful clinical solutions, aiming to transition spatial biology from research into routine diagnostics within the next 18 months. The funding will accelerate the development of proprietary diagnostic tests, facilitate key validation studies, and establish strategic partnerships, thereby enhancing cancer treatment decision-making processes.
Source link
